Stuttgart - Delayed Quote EUR

Axsome Therapeutics Inc (19X.SG)

102.25

-2.10

(-2.01%)

At close: January 31 at 9:34:16 PM GMT+1

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

The FDA approves AXSM's Symbravo for the acute treatment of migraine with or without aura in adults. The latest nod diversifies its commercial portfolio.

Zacks yesterday

AXSM
Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

NEW YORK, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, will host a virtual investor event and conference call today at 8:00 AM Eastern Time to discuss the U.S. Food and Drug Administration (FDA) approval of SYMBRAVO®, a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack. Experience the interactive M

GlobeNewswire yesterday

AXSM
Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

A single oral dose of SYMBRAVO provided rapid migraine pain freedom and return to normal functioning within 2 hours, and sustained efficacy through 24 and 48 hours 85% and 77% of patients treated with a single dose of SYMBRAVO did not require migraine rescue medication within 24 hours in two Phase 3 studies SYMBRAVO demonstrated superior efficacy across a broad range of migraine severity (mild, moderate, and severe), and in head-to-head evaluation SYMBRAVO incorporates Axsome’s rapid absorption

GlobeNewswire 2 days ago

AXSM
Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it will report its financial results for the fourth quarter and full year of 2024 on Tuesday, February 18, 2025, before the opening of the U.S. financial markets. Axsome management will then host a conference call at 8:00 a.m. Eastern Time to discuss these results and provide a business upda

GlobeNewswire 10 days ago

AXSM
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Biotech stocks put up a split showing at JPM, where names like BridgeBio, ARS and Harmony stood out with strong preliminary reports.

Investor's Business Daily 19 days ago

AXSM

BBIO

HRMY
Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

Auvelity preliminary 4Q and full year 2024 net product sales of $92.6 million and $291.4 million, respectively Sunosi preliminary 4Q and full year 2024 net product revenue of $25.7 million and $93.8 million, respectively NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced preliminary net product revenue for the fourth quarter and full year en

GlobeNewswire 19 days ago

AXSM
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Axsome Therapeutics, Inc. ( NASDAQ:AXSM ) is possibly approaching a major achievement in its business, so we would like...

Simply Wall St. 26 days ago

AXSM
Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 (dextromethorphan-bupropion) in Alzheimer's disease agitation. The ACCORD-2 Phase 3 trial achieved the primary endpoint with AXS-05 statistically significantly delaying the time to relapse of agitation, demonstrating a 3.6-fold lower risk of relapse compared to placebo. AXS-05 also met the key secondary endpoint (relapse prevention, p=0.001). Further, AXS-05 reduced the w

Benzinga last month

AXSM
Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Shares of Axsome Therapeutics dropped Monday on mixed test results for its Alzheimer's disease agitation treatment.

Investor's Business Daily last month

AXSM
Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

ACCORD-2 Phase 3 trial in Alzheimer’s disease agitation achieves primary endpoint compared to placebo (p=0.001, time to relapse) ACCORD-2 Phase 3 trial achieves key secondary endpoint compared to placebo (p=0.001, prevention of relapse of Alzheimer’s disease agitation) AXS-05 reduced worsening of Alzheimer’s disease overall compared to placebo in ACCORD-2 Phase 3 trial (p<0.001, CGI-S Alzheimer’s disease overall clinical status) ADVANCE-2 trial did not demonstrate statistical significance on pri

GlobeNewswire last month

AXSM
Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks last month

AXSM
Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

On Tuesday, Axsome Therapeutics Inc (NASDAQ:AXSM) said AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) in Phase 3 ENCORE trial. AXS-12 was also well tolerated with long-term dosing, and its safety profile was consistent with that observed in previously completed trials. The primary endpoint was achieved with patients randomized to switch to placebo experiencing a mean increase of 10.29 cataplexy attacks per week compar

Benzinga 2 months ago

AXSM
Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...

Simply Wall St. 2 months ago

AXSM
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) Statistically significant improvement in cognition compared to placebo (p=0.011, NSAQ) Statistically significant improvement in narcolepsy overall compared to placebo (p=0.024, PGI-C) Cataplexy response (≥50% improvement) achieved by 72% of patients at 1 month and 82% at 6 months Improvement in excessive daytime sleepiness (EDS), assessed by the CGI-C, achieved by 84% of

GlobeNewswire 2 months ago

AXSM
Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

AXSM posts better-than-expected third-quarter results. Stock rises in response to the results and strong sales uptake of Auvelity.

Zacks 2 months ago

AXSM
Q3 2024 Axsome Therapeutics Inc Earnings Call

Q3 2024 Axsome Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 2 months ago

AXSM
Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

AXSM earnings call for the period ending September 30, 2024.

Motley Fool 2 months ago

AXSM
Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains

Investors rally behind Axsome's explosive growth, with FDA approvals and breakthrough drugs driving momentum.

GuruFocus.com 2 months ago

AXSM
Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth Auvelity® 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth Sunosi® 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth Second expansion of Auvelity psychiatry sales force planned for 1Q 2025 NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025 Topline results of ADVANCE-2 an

GlobeNewswire 2 months ago

AXSM
Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced eight presentations spanning its innovative portfolio of late-stage products and product candidates in psychiatry and neurology at NEI Congress 2024, being held Nov. 7 - Nov. 10, 2024, in Colorado Springs, Colorado. Details for the presentations are as follows: Majo

GlobeNewswire 2 months ago

AXSM

Performance Overview

Return	19X.SG	S&P 500
YTD	+24.27%	+2.26%
1-Year	+22.72%	+22.65%
3-Year	+365.41%	+36.30%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Axsome Therapeutics Inc (19X.SG)

Axsome Gets FDA Nod for New Migraine Drug Symbravo, Stock Rises

Axsome Therapeutics Hosts SYMBRAVO® FDA Approval Virtual Investor Event with Expert Thought Leader

Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults

Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18

BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.

Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue

Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Profit Outlook

Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results

Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report?

Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says

Axsome Therapeutics' (NASDAQ:AXSM) growing losses don't faze investors as the stock ascends 5.5% this past week

Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy

Axsome's Q3 Earnings Beat, Auvelity Drives Sales Growth, Stock Up

Q3 2024 Axsome Therapeutics Inc Earnings Call

Axsome Therapeutics (AXSM) Q3 2024 Earnings Call Transcript

Axsome Hits 52-Week High After Surging Nearly 5%--FDA Milestones Could Fuel Even Bigger Gains

Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024

Performance Overview